Literature DB >> 22379425

Antiemetics: american society of clinical oncology clinical practice guideline update.

Ethan Basch1, Paul J Hesketh, Mark G Kris, Ann Alexis Prestrud, Sarah Temin, Gary H Lyman.   

Abstract

ASCO's update to its antiemetics guideline now includes an evaluation of evidence on complementary antiemetic therapy.

Year:  2011        PMID： 22379425      PMCID： PMC3219469          DOI： 10.1200/JOP.2011.000397

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  1 in total

Review 1.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544
  1 in total
  21 in total

1.  Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin.

Authors:  Hironori Nakamura; Haruko Yokoyama; Risa Takayanagi; Koichi Yoshimoto; Akihiro Nakajima; Kiyoshi Okuyama; Osamu Iwase; Yasuhiko Yamada
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-01-28       Impact factor: 2.441

2.  Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation.

Authors:  Masatoshi Sakurai; Takehiko Mori; Jun Kato; Yuya Koda; Taku Kikuchi; Sumiko Kohashi; Masuho Saburi; Takaaki Toyama; Yoshinobu Aisa; Tomonori Nakazato; Noriko Beppu; Soichiro Tsuda; Naoyuki Shigematsu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2014-03-12       Impact factor: 2.490

3.  Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life.

Authors:  Nibal Abunahlah; Mesut Sancar; Faysal Dane; Mustafa Kerem Özyavuz
Journal:  Int J Clin Pharm       Date:  2016-10-28

4.  Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients.

Authors:  Sun Young Rha; Yeonhee Park; Su Kyung Song; Chung Eun Lee; Jiyeon Lee
Journal:  Support Care Cancer       Date:  2016-03-16       Impact factor: 3.603

Review 5.  Efficacy, tolerability, and safety of cannabinoids for chemotherapy-induced nausea and vomiting--a systematic review of systematic reviews.

Authors:  S Tafelski; W Häuser; M Schäfer
Journal:  Schmerz       Date:  2016-02       Impact factor: 1.107

6.  Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.

Authors:  Icro Meattini; Giulio Francolini; Vieri Scotti; Carla De Luca Cardillo; Sabrina Cappelli; Fiammetta Meacci; Ilaria Francesca Furfaro; Cristina Muntoni; Silvia Scoccianti; Beatrice Detti; Monica Mangoni; Jacopo Nori; Lorenzo Orzalesi; Massimiliano Fambrini; Simonetta Bianchi; Lorenzo Livi
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

7.  Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors.

Authors:  Sonam Puri; Kelly A Hyland; Kristine Crowe Weiss; Gillian C Bell; Jhanelle E Gray; Richard Kim; Hui-Yi Lin; Aasha I Hoogland; Brian D Gonzalez; Ashley M Nelson; Anita Y Kinney; Stacy M Fischer; Daneng Li; Paul B Jacobsen; Howard L McLeod; Heather S L Jim
Journal:  Support Care Cancer       Date:  2018-03-15       Impact factor: 3.603

Review 8.  2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential.

Authors:  Ian Olver; Christina H Ruhlmann; Franziska Jahn; Lee Schwartzberg; Bernardo Rapoport; Cynthia N Rittenberg; Rebecca Clark-Snow
Journal:  Support Care Cancer       Date:  2016-08-30       Impact factor: 3.603

Review 9.  Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Authors:  Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

10.  National characteristics of Emergency Department visits by patients with cancer in the United States.

Authors:  Joann Hsu; John P Donnelly; Justin Xavier Moore; Karen Meneses; Grant Williams; Henry E Wang
Journal:  Am J Emerg Med       Date:  2018-03-13       Impact factor: 2.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.